Now showing items 1-4 of 4

    • Antiretroviral therapy improves cognitive impairment in HIV individuals in Sub-Saharan Africa 

      Sacktor, N.; Nakasujja, N.; Skolasky, R.; Robertson, K.; Wong, M.; Musisi, S.; Ronald, A.; Katabira, E. (American Academy of Neurology (AAN), 2006)
      Abstract—Background: Highly active antiretroviral therapy (HAART) can improve cognitive performance in some patients with HIV-associated cognitive impairment in the United States. The effect of HAART on HIV dementia ...
    • Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa 

      Wong, M. H.; Robertson, K.; Nakasujja, N; Skolasky, R.; Musisi, S.; Katabira, E.; McArthur, J. C.; Ronald, A.; Sacktor, N. (American Academy of Neurology, 2007)
      Objective: To measure the frequency and associated risk factors of HIV dementia in an HIV clinic in Kampala, Uganda. Methods: We systematically sampled 78 HIV-seropositive (HIV ) patients from an ambulatory HIV ...
    • Human immunodeficiency virus neurological complications: An overview of the Ugandan experience. 

      Nakasujja, N; Musisi, S.; Robertson, K.; Wong, M.; Sacktor, N.; Ronald, A. (Journal of NeuroVirology, 2005)
      Sub-Saharan Africa, which has about 12% of the global population, is home to almost 70% of individuals infected with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). A recent survey by the ...
    • Rolling out antiretrovirals in Africa: there are still challenges ahead 

      Colebunders, R.; Ronald, A.; Katabira, E.; Sande, M. (Infectious Diseases Society of America, 2005-08)
      In their article “Lessons Learned from Highly Active Antiretroviral Therapy in Africa,” Akileswaran et al. [1] review the effectiveness of HAART programs in Africa. They report positive health outcomes, including high ...